share_log

Med-X Secures High-Priority Order to Address Bed Bug Issue Impacting the Republic of Singapore

Med-X Secures High-Priority Order to Address Bed Bug Issue Impacting the Republic of Singapore

Med-X 獲得解決影響新加坡共和國的臭蟲問題的高度優先命令
Accesswire ·  2023/12/14 21:31

Med-X Fulfills Bulk Order to Address Urgent Bed Bug Issue Impacting Singapore

Med-X 完成批量訂單,以解決影響新加坡的緊急臭蟲問題

All-Natural Nature-Cide Products Provide a Safe Alternative to Control Pests in Sensitive Areas such as Homes and Hotels

全天然 Nature-Cide 產品爲控制家庭和酒店等敏感區域的害蟲提供了安全的替代方案

LOS ANGELES, CA / ACCESSWIRE / December 14, 2023 / Med-X, Inc., a leading innovator of all-natural green scene solutions addressing the pest control, health and wellness markets, announced today that it has secured a high-priority Nature-Cide order to address an urgent bed bug issue impacting the Republic of Singapore.

加利福尼亞州洛杉磯/ACCESSWIRE /2023 年 12 月 14 日/ Med-X, Inc., 一家針對害蟲防治、健康和保健市場的全天然綠色場景解決方案的領先創新者今天宣佈,它已獲得一項高度優先的Nature-Cide命令,以解決影響新加坡共和國的緊急臭蟲問題。

The Republic of Singapore is an island nation in Southeast Asia, home to a population of 5.5 million. As a global travel hub, the country has seen a significant increase in bed bug cases, with one leading pest control firm operating in Singapore reporting a 40% increase in bed bug cases over the past two months.

新加坡共和國是東南亞的一個島國,擁有550萬人口。作爲全球旅遊中心,該國的臭蟲病例顯著增加,一家在新加坡運營的領先害蟲防治公司報告說,臭蟲病例比過去增加了40% 兩個月

To address the urgent issue of bed bugs currently impacting Singapore and other markets in Southeast Asia, Med-X recently fulfilled a high-priority wholesale order for several variants of its flagship Nature-Cide pest control products from Singapore. Nature-Cide products can be found in all of the largest professional supply chain distribution centers throughout the United States, while also having been recently positioned with an international distribution agreement with Ensystex, which allows pest control professionals in various countries to access this proven all-natural brand.

爲了解決目前影響新加坡和東南亞其他市場的臭蟲這一緊迫問題,Med-X最近完成了其幾種變體的高度優先批發訂單 旗艦 Nature-Cide 害蟲防治產品 來自新加坡。Nature-Cide產品可以在美國所有最大的專業供應鏈配送中心找到,而最近也有 與Ensystemx簽訂了國際分銷協議,這使不同國家的害蟲防治專業人員能夠使用這個久經考驗的全天然品牌。

Pictured Above: Nature-Cide Product Examples that were Shipped to Singapore

上圖:運往新加坡的 Nature-Cide 產品示例

Matthew Mills, Chief Executive Officer of Med-X, said: "I am proud of our team's ability to take urgent action, supporting the immediate-term need of our valued clients - for a safe, all-natural alternative to chemical pesticides for treating bed bug infestations in the Republic of Singapore.

Med-X首席執行官Matthew Mills表示:“我爲我們的團隊能夠採取緊急行動,支持我們尊貴客戶的近期需求——尋求一種安全、全天然的化學農藥替代品來治療新加坡共和國的臭蟲侵擾,我爲此感到自豪。

"The benefits of using an all-natural product such as Nature-Cide in sensitive areas - such as homes and hotels - is abundantly clear, proving safe for both pest control professionals and their customers. As ministries around the world continue to ban chemical pesticides without having proven solutions in place to combat these types of common pests, it could give all-natural products like Nature-Cide the opportunity to solve these issues, which gives strong peace of mind that furthers confidence that no harm will come from this type of all-natural application. We look forward to other ministries loosening restrictions globally for natural solutions to allow Med-X to further build our long-term partnerships with tier-1 global customers, a key component of our long-term mission to drive sustainable, long-term value for my fellow shareholders," concluded Mills.

“在敏感區域(例如家庭和酒店)使用諸如Nature-Cide之類的全天然產品的好處是顯而易見的,事實證明,對害蟲防治專業人員及其客戶都是安全的。由於世界各部委在沒有針對此類常見害蟲的成熟解決方案的情況下繼續禁止使用化學殺蟲劑,這可能使像Nature-Cide這樣的全天然產品有機會解決這些問題,從而使人們高枕無憂,從而增強人們對這種全天然應用不會造成傷害的信心。我們期待其他部委在全球範圍內放鬆對天然解決方案的限制,使Med-X能夠進一步與全球一級客戶建立長期合作伙伴關係,這是我們爲其他股東創造可持續長期價值的長期使命的關鍵組成部分,” 米爾斯總結道。

About Med-X, Inc.

關於 Med-X, Inc.

Med-X, Inc. is a leading innovator of biological pest control solutions addressing both consumer and professional markets globally. Nature-Cide - the Company's flagship product line - is a safer, all-natural alternative to conventional chemical products, formulated to kill or repel a wide variety of pests. Med-X's comprehensive go-to-market strategy includes leveraging strategic partnerships alongside an integrated e-commerce, brick and mortar and on-site services presence in key markets. For more information, please visit our website at .

Med-X, Inc. 是生物害蟲防治解決方案的領先創新者,面向全球消費者和專業市場。Nature-Cide是公司的旗艦產品線,是傳統化學產品的更安全、全天然的替代品,其配方旨在殺死或擊退各種害蟲。Med-X 的全面進入市場戰略包括利用戰略合作伙伴關係,以及在關鍵市場開展綜合電子商務、實體店和現場服務。欲了解更多信息,請訪問我們的網站 。

Disclaimer and Forward-Looking Statements

免責聲明和前瞻性陳述

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities. Any offers, solicitations or offers to buy, or any sale of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended (the "Securities Act"). This announcement is being issued in accordance with Rule 135 of the Securities Act. This press release may contain forward-looking statements regarding projected business performance, operating results, financial condition, and other aspects of the company, expressed by such language as "expected," "anticipated," "projected" and "forecasted." Please be advised that such statements are estimates only and there is no assurance that the results stated or implied by forward-looking statements will actually be realized by the company. Forward-looking statements may be based on management assumptions that prove to be wrong. The Company and its business are subject to substantial risks and potential events beyond its control that would cause material differences between predicted results and actual results, including the Company incurring operating losses and experiencing unexpected material adverse events.

本新聞稿不構成出售要約或徵求購買任何證券的要約。任何證券的要約、招標或要約購買或任何出售都將根據經修訂的1933年《證券法》(“證券法”)的註冊要求提出。本公告是根據《證券法》第135條發佈的。本新聞稿可能包含有關預計業務業績、經營業績、財務狀況和公司其他方面的前瞻性陳述,用 “預期”、“預期” 和 “預測” 等語言表達。請注意,此類陳述僅是估計值,無法保證前瞻性陳述所陳述或暗示的結果會由公司實際實現。前瞻性陳述可能基於被證明是錯誤的管理假設。公司及其業務面臨其無法控制的重大風險和潛在事件,這些風險和潛在事件將導致預期業績與實際業績之間存在重大差異,包括公司蒙受營業虧損和遇到意想不到的重大不利事件。

Investor Relations Contact

投資者關係聯繫人

Lucas Zimmerman
Director
MZ Group - MZ North America
262-357-2918
MXRX@mzgroup.us

盧卡斯·齊默爾曼
導演
MZ 集團-MZ 北美
262-357-2918
MXRX@mzgroup.us

SOURCE: Med-X, Inc.

資料來源:Med-X, Inc.


View the original press release on accesswire.com
在 accesswire.com 上查看原始新聞稿

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論